Study S000958

Comparative Clinical Study to Evaluate the Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes Inadequately Controlled by Insulin Therapy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06762314
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 114
Start: 2025-01-20
Primary completion: 2026-01-20
Lead sponsor: Mostafa Bahaa
Conditions: Diabetes
Interventions: DRUG:Insulin; DRUG:Semaglutide; DRUG:Empagliflozin
Results posted: FALSE

Registered primary outcomes

The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment. [3 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.